Publisher's Synopsis
Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Simvastatin;;Editorial: "Two landmark clinical outcome trials published in the past decade - the Scandinavian Simvastatin Survival Study (4S) and the Heart Protection Study (HPS) - confirmed reductions in CHD events as well as all-cause mortality and showed no increase in non-cardiovascular mortality or cancer in the treatment groups." Disease Overview: "Raised cholesterol, in particular low density lipoprotein cholesterol (LDL-C), appears to be a pivotal risk factor in the development of coronary heart disease (CHD)." Drug Review: "In general, simvastatin elicited superior improvements in HDL-C, compared with atorvastatin, fluvastatin and pravastatin and was associated with similar or greater reductions in LDL-C, depending on the comparator statin." Improving Practice: "The burden of cardiovascular disease in the UK is large and is likely to increase as the population ages. At current rates, nearly half the population will die from a cardiovascular cause and so the problem impacts on all healthcare professionals."
